Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_205_библиотеки_им_акад_М_И_Перельмана
.pdf
122 The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
development of depression in susceptible patients (Schmidt and Rubinow 2009;
Schmidt et al. 2015).
Several psychotropic medications commonly prescribed for mood disorders,
chiefly antipsychotics and antidepressants, but also mood stabilizers, may affect the
HPG axis (Drobnis and Nangia 2017). Both first- and second-generation antipsychot
ics can indeed block the dopamine receptors (mainly D
prolactin, decreasing gonadotropin release. This effect is less frequent with the use of
some second-generation compounds, such as aripiprazole and cariprazine, which
have a partial agonist effect on dopamine receptors. Prolactin levels also may be increased by several antidepressants, again through their effect on dopamine (inhibition of the reuptake). Additionally, lithium has been shown to increase prolactin and
LH levels and decrease sex hormones. Anticonvulsants generally decrease free or bio
available testosterone and have variable effects on the other reproductive hormones
(Drobnis and Nangia 2017). Valproate has been clearly linked with high rates of men
strual abnormalities, hyperandrogenism, and polycystic ovary syndrome in patients
with bipolar disorder (O’Donovan et al. 2002).
As discussed, the clinical relevance of the HPG axis in mood disorders may lie in
its overlap with the HPA axis. Interestingly, the ginsenoside Rg1—one of the active
compounds of the plant genus Panax (ginseng)—has several biological functions, including sex hormone–like activities and GR modulation. Mou et al. (2017) reported
that Rg1 had antidepressant effects in mice, by modulating both the HPA and HPG
axes; specifically, mice treated with Rg1 presented significantly lessened depressivelike symptoms, together with reduced GC levels and increased testosterone levels.
) and increase the levels of
2
-
-
-
Hypothalamic-Neurohypophysial System
Due to the role of the neurohypophysial system in depression and its intricate connections with other neuroendocrine and immune pathways, it is not surprising that
AVP and OT have been studied for their therapeutic potential. Antagonists of the
AVP receptor V1b have been demonstrated to have antidepressant effects (Neumann
and Landgraf 2012). However, Griebel et al. (2012) reported results from three ran
domized, double-blind, placebo-controlled studies of patients with depression who
were taking SSR149415—an AVP V1b receptor antagonist—for 8 weeks, with no uni
vocal results. Of note, SIADH could be caused by several drugs commonly prescribed
for mood disorders, such as many antidepressants (mainly SSRIs, but also tricyclics,
monoamine oxidase inhibitors, and venlafaxine) and anticonvulsants (e.g., valproic
acid, carbamazepine, oxcarbazepine) (Liamis et al. 2008; Spasovski et al. 2014). Even
if the precise mechanisms have not been completely clarified, SIADH could be due to
an increase in ADH secretion caused by 5-HT and norepinephrine (De Picker et al.
2014) or to a direct effect on renal sensitivity to ADH (Sachdeo et al. 2002).
Preclinical and clinical evidence indicate that OT, administered either peripherally
or centrally, may counteract depression (Matsuzaki et al. 2012; Neumann and Landgraf 2012). These antidepressant effects are not blocked by the administration of an OT
receptor antagonist (Acevedo-Rodriguez et al. 2015), suggesting that they are differ
ently mediated, probably through the AVP receptors (Manning et al. 2012). Interestingly, OT could exert an antidepressant effect by increasing dopaminergic transmission,
via D
receptor activation, in the medial prefrontal cortex (Li et al. 2020). The adminis-
1
-
-
-
123 Psychoneuroendocrinology of Mood Disorders
https://t.me/med1917
tration of OT to prevent postpartum depression is still under debate. Some studies
found that OT may negatively impact maternal mood (Kroll-Desrosiers et al. 2017;
Mah 2016), although other evidence suggests a protective role for future development
of postpartum depression, even without immediate effects on maternal mood (Takács
et al. 2019).
Conclusion
Mood disorders are profoundly linked to biological alterations in the body. We should
therefore think of mental health as a part of the whole individual’s well-being. The
human organism is a complex orchestra in which all the instruments play together in
order to maintain homeostasis; an imbalance within one system could cause the disruption of others. Through the investigation of the interface between body and mind,
psychoneuroendocrinology provides a broader perspective for approaching mental
health. Even though current findings are not definitive and some critical issues remain, research in this field may shed light on the biological mechanisms underpinning mood disorders, identify new paths for diagnosis and treatment, and ultimately
lead to delivery of better patient care.
References
Acevedo-Rodriguez A, Mani SK, Handa RJ: Oxytocin and estrogen receptor beta in the brain:
an overview. Front Endocrinol (Lausanne) 6:160, 2015 26528239
Agustini B, Bocharova M, Walker AJ, et al: Has the sun set for seasonal affective disorder and
HPA axis studies? A systematic review and future prospects. J Affect Disord 256:584–593,
2019 31299439
Alhajji L, Nemeroff CB: Personalized medicine and mood disorders. Psychiatr Clin North Am
38(3):395–403, 2015 26300030
Almeida OP, Yeap BB, Hankey GJ, et al: Low free testosterone concentration as a potentially
treatable cause of depressive symptoms in older men. Arch Gen Psychiatry 65(3):283–289,
2008 18316674
Amann BL, Radua J, Wunsch C, et al: Psychiatric and physical comorbidities and their impact
on the course of bipolar disorder: a prospective, naturalistic 4-year follow-up study. Bipolar Disord 19(3):225–234, 2017 28544558
Anacker C, Zunszain PA, Cattaneo A, et al: Antidepressants increase human hippocampal neu-
rogenesis by activating the glucocorticoid receptor. Mol Psychiatry 16(7):738–750, 2011
21483429
Angst J, Gamma A, Benazzi F, et al: Diagnostic issues in bipolar disorder. Eur Neuropsycho-
pharmacol 13 (suppl 2):S43–S50, 2003 12957719
Ashley NT, Demas GE: Neuroendocrine-immune circuits, phenotypes, and interactions. Horm
Behav 87:25–34, 2017 27765499
Baek JH, Kang ES, Fava M, et al: Thyroid stimulating hormone and serum, plasma, and platelet
brain-derived neurotrophic factor during a 3-month follow-up in patients with major de
pressive disorder. J Affect Disord 169:112–117, 2014 25189990
Barbuti M, Carvalho AF, Köhler CA, et al: Thyroid autoimmunity in bipolar disorder: a system-
atic review. J Affect Disord 221:97–106, 2017 28641149
Bauer MS, Whybrow PC, Winokur A: Rapid cycling bipolar affective disorder, I: association
with grade I hypothyroidism. Arch Gen Psychiatry 47(5):427–432, 1990 2109970
-
124 The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
Bauer M, Goetz T, Glenn T, Whybrow PC: The thyroid-brain interaction in thyroid disorders
and mood disorders. J Neuroendocrinol 20(10):1101–1114, 2008 18673409
Bei E, Salpeas V, Pappa D, et al: Phosphorylation status of glucocorticoid receptor, heat shock
protein 70, cytochrome c and Bax in lymphocytes of euthymic, depressed and manic bipo
lar patients. Psychoneuroendocrinology 34(8):1162–1175, 2009 19359101
Bei ES, Salpeas V, Alevizos B, et al: Pattern of heat shock factor and heat shock protein expres-
sion in lymphocytes of bipolar patients: increased HSP70-glucocorticoid receptor heterocomplex. J Psychiatr Res 47(11):1725–1736, 2013 23938235
Belvederi Murri M, Pariante C, Mondelli V, et al: HPA axis and aging in depression: systematic
review and meta-analysis. Psychoneuroendocrinology 41:46–62, 2014 24495607
Belvederi Murri M, Prestia D, Mondelli V, et al: The HPA axis in bipolar disorder: systematic
review and meta-analysis. Psychoneuroendocrinology 63:327–342, 2016 26547798
Binder EB: The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis
and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34 (suppl
1):S186–S195, 2009 19560279
Binder EB, Salyakina D, Lichtner P, et al: Polymorphisms in FKBP5 are associated with in-
creased recurrence of depressive episodes and rapid response to antidepressant treatment.
Nat Genet 36(12):1319–1325, 2004 15565110
Block TS, Kushner H, Kalin N, et al: Combined analysis of mifepristone for psychotic depres-
sion: plasma levels associated with clinical response. Biol Psychiatry 84(1):46–54, 2018
29523415
Bocchetta A, Traccis F, Mosca E, et al: Bipolar disorder and antithyroid antibodies: review and
case series. Int J Bipolar Disord 4(1):5, 2016 26869176
Brouwer JP, Appelhof BC, Hoogendijk WJ, et al: Thyroid and adrenal axis in major depression:
a controlled study in outpatients. Eur J Endocrinol 152(2):185–191, 2005 15745924
Brummelte S, Galea LAM: Postpartum depression: etiology, treatment and consequences for
maternal care. Horm Behav 77:153–166, 2016 26319224
Butler MI, Sandhu K, Cryan JF, Dinan TG: From isoniazid to psychobiotics: the gut microbiome
as a new antidepressant target. Br J Hosp Med (Lond) 80(3):139–145, 2019 30860919
Carvalho AF, Machado JR, Cavalcante JL: Augmentation strategies for treatment-resistant de-
pression. Curr Opin Psychiatry 22(1):7–12, 2009 19122528
Cherian K, Schatzberg AF, Keller J: HPA axis in psychotic major depression and schizophrenia
spectrum disorders: cortisol, clinical symptomatology, and cognition. Schizophr Res
213:72–79, 2019 31307859
Cobo J, Giménez-Palop O, Patró E, et al: Lack of confirmation of thyroid endophenotype in
bipolar disorder type I and their first-degree relatives. Psychoneuroendocrinology 51:351–
364, 2015 25462907
Cohen BM, Sommer BR, Vuckovic A: Antidepressant-resistant depression in patients with
comorbid subclinical hypothyroidism or high-normal TSH levels. Am J Psychiatry
175(7):598–604, 2018 29961367
Cole DP, Thase ME, Mallinger AG, et al: Slower treatment response in bipolar depression pre-
dicted by lower pretreatment thyroid function. Am J Psychiatry 159(1):116–121, 2002
11772699
Cousins L, Goodyer IM: Antidepressants and the adolescent brain. J Psychopharmacol
29(5):545–555, 2015 25744620
Daban C, Vieta E, Mackin P, Young AH: Hypothalamic-pituitary-adrenal axis and bipolar dis-
order. Psychiatr Clin North Am 28(2):469–480, 2005 15826743
Delvecchio G, Altamura AC, Soares JC, Brambilla P: Pituitary gland in bipolar disorder and
major depression: evidence from structural MRI studies. J Affect Disord 218:446–450, 2017
28412090
De Picker L, Van Den Eede F, Dumont G, et al: Antidepressants and the risk of hyponatremia:
a class-by-class review of literature. Psychosomatics 55(6):536–547, 2014 25262043
Deshauer D, Duffy A, Meaney M, et al: Salivary cortisol secretion in remitted bipolar patients
and offspring of bipolar parents. Bipolar Disord 8(4):345–349, 2006 16879135
-
125 Psychoneuroendocrinology of Mood Disorders
https://t.me/med1917
Dickens MJ, Pawluski JL: The HPA axis during the perinatal period: implications for perinatal
depression. Endocrinology 159(11):3737–3746, 2018 30256957
Drobnis EZ, Nangia AK: Psychotropics and male reproduction. Adv Exp Med Biol 1034:63–101,
2017 29256128
Duval F, Mokrani MC, Monreal J, et al: Interaction between the serotonergic system and HPA
and HPT axes in patients with major depression: implications for pathogenesis of suicidal
behavior. Dialogues Clin Neurosci 4(4):417, 2002 22033833
Elder GJ, Wetherell MA, Barclay NL, Ellis JG: The cortisol awakening response—applications
and implications for sleep medicine. Sleep Med Rev 18(3):215–224, 2014 23835138
Ellenbogen MA, Hodgins S, Walker CD: High levels of cortisol among adolescent offspring of
parents with bipolar disorder: a pilot study. Psychoneuroendocrinology 29(1):99–106, 2004
14575732
Ellenbogen MA, Santo JB, Linnen AM, et al: High cortisol levels in the offspring of parents with
bipolar disorder during two weeks of daily sampling. Bipolar Disord 12(1):77–86, 2010
20148869
Ellenbogen MA, Hodgins S, Linnen AM, Ostiguy CS: Elevated daytime cortisol levels: a bio-
marker of subsequent major affective disorder? J Affect Disord 132(1–2):265–269, 2011
21329985
Engelmann M, Landgraf R, Wotjak CT: The hypothalamic-neurohypophysial system regulates
the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neu
roendocrinol 25(3-4):132–149, 2004 15589266
Epstein CM, Houfek JF, Rice MJ, et al: Early life adversity and depressive symptoms predict
cortisol in pregnancy. Arch Women Ment Health 23(3):379–389, 2020 31289940
Ezzaher A, Haj Mouhamed D, Mechri A, et al: Thyroid function and lipid profile in bipolar I
patients. Asian J Psychiatr 4(2):139–143, 2011 23051081
Fam J, Rush AJ, Burt T, et al: Thyroid autoimmune antibodies and major depressive disorder
in women. Ann Acad Med Singapore 44(8):284–289, 2015 26477960
Farzi A, Fröhlich EE, Holzer P: Gut microbiota and the neuroendocrine system. Neurothera-
peutics 15(1):5–22, 2018 29380303
Feng G, Kang C, Yuan J, et al: Neuroendocrine abnormalities associated with untreated first
episode patients with major depressive disorder and bipolar disorder. Psychoneuroendo
crinology 107:119–123, 2019 31125758
Ferrier IN, Anderson IM, Barnes J, et al; ADD Study Team: Randomised controlled trial of Anti-
glucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD
Study). Efficacy and Mechanism Evaluation (Southampton [UK]: NIHR Journals Library)
2(4), 2015 26086063
Fischer S, Ehlert U, Amiel Castro R: Hormones of the hypothalamic-pituitary-gonadal (HPG)
axis in male depressive disorders—a systematic review and meta-analysis. Front Neuro
endocrinol 55:100792, 2019a 31557486
Fischer S, Gardini ES, Haas F, Cleare AJ: Polymorphisms in genes related to the hypothalamic-
pituitary-adrenal axis and antidepressant response—systematic review. Neurosci Biobehav Rev 96:182–196, 2019b 30465786
Fornaro M, Anastasia A, Novello S, et al: The emergence of loss of efficacy during antidepres-
sant drug treatment for major depressive disorder: an integrative review of evidence,
mechanisms, and clinical implications. Pharmacol Res 139:494–502, 2019 30385364
Fountoulakis KN, Kantartzis S, Siamouli M, et al: Peripheral thyroid dysfunction in depression.
World J Biol Psychiatry 7(3):131–137, 2006 16861138
Fries GR, Vasconcelos-Moreno MP, Gubert C, et al: Hypothalamic-pituitary-adrenal axis dys-
function and illness progression in bipolar disorder. Int J Neuropsychopharmacol
18(1):pyu043, 2014 25522387
Frye MA, Denicoff KD, Bryan AL, et al: Association between lower serum free T4 and greater
mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry
156(12):1909–1914, 1999 10588404
-
-
-
126 The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
Furuta M, Numakawa T, Chiba S, et al: Estrogen, predominantly via estrogen receptor alpha,
attenuates postpartum-induced anxiety- and depression-like behaviors in female rats. En
docrinology 154(10):3807–3816, 2013 23913447
Glynn LM, Davis EP, Sandman CA: New insights into the role of perinatal HPA-axis dysregu-
lation in postpartum depression. Neuropeptides 47(6):363–370, 2013 24210135
Griebel G, Beeské S, Stahl SM: The vasopressin V(1b) receptor antagonist SSR149415 in the
treatment of major depressive and generalized anxiety disorders: results from 4 random
ized, double-blind, placebo-controlled studies. J Clin Psychiatry 73(11):1403–1411, 2012
23146246
Guintivano J, Arad M, Gould TD, et al: Antenatal prediction of postpartum depression with
blood DNA methylation biomarkers. Mol Psychiatry 19(5):560–567, 2014 23689534
Hage MP, Azar ST: The link between thyroid function and depression. J Thyroid Res
2012:590648, 2012 22220285
Hammarström A, Lehti A, Danielsson U, et al: Gender-related explanatory models of depres-
sion: a critical evaluation of medical articles. Public Health 123(10):689–693, 2009 19853877
Hardeveld F, Spijker J, Vreeburg SA, et al: Increased cortisol awakening response was associ-
ated with time to recurrence of major depressive disorder. Psychoneuroendocrinology
50:62–71, 2014 25179322
Havermans R, Nicolson NA, Berkhof J, deVries MW: Patterns of salivary cortisol secretion and
responses to daily events in patients with remitted bipolar disorder. Psychoneuroendocri
nology 36(2):258–265, 2011 20732746
Hillegers MHJ, Reichart CG, Wals M, et al: Signs of a higher prevalence of autoimmune thy-
roiditis in female offspring of bipolar parents. Eur Neuropsychopharmacol 17(6–7):394–
399, 2007 17140771
Holsboer F, Ising M: Central CRH system in depression and anxiety—evidence from clinical
studies with CRH1 receptor antagonists. Eur J Pharmacol 583(2–3):350–357, 2008 18272149
Huang CC, Wei IH, Chou YH, Su TP: Effect of age, gender, menopausal status, and ovarian hor-
monal level on rTMS in treatment-resistant depression. Psychoneuroendocrinology
33(6):821–831, 2008 18468810
Hung PL, Huang CC, Huang HM, et al: Thyroxin treatment protects against white matter in-
jury in the immature brain via brain-derived neurotrophic factor. Stroke 44(8):2275–2283,
2013 23715956
Ising M, Maccarrone G, Brückl T, et al: FKBP5 gene expression predicts antidepressant treat-
ment outcome in depression. Int J Mol Sci 20(3):485, 2019 30678080
Joffe H, Kim DR, Foris JM, et al: Menstrual dysfunction prior to onset of psychiatric illness is
reported more commonly by women with bipolar disorder than by women with unipolar
depression and healthy controls. J Clin Psychiatry 67(2):297–304, 2006 16566627
Jones C, Barrera I, Brothers S, et al: Oxytocin and social functioning. Dialogues Clin Neurosci
19(2):193–201, 2017 28867943
Jucevičiūtė N, Žilaitienė B, Aniulienė R, Vanagienė V: The link between thyroid autoimmunity,
depression and bipolar disorder. Open Med (Wars) 14:52–58, 2019 30775452
Juruena MF, Pariante CM, Papadopoulos AS, et al: Prednisolone suppression test in depres-
sion: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J
Psychiatry 194(4):342–349, 2009 19336786
Kanayama G, Amiaz R, Seidman S, Pope HG Jr: Testosterone supplementation for depressed
men: current research and suggested treatment guidelines. Exp Clin Psychopharmacol
15(6):529–538, 2007 18179305
Katz ER, Stowe ZN, Newport DJ, et al: Regulation of mRNA expression encoding chaperone
and co-chaperone proteins of the glucocorticoid receptor in peripheral blood: association
with depressive symptoms during pregnancy.
Kimmel M, Clive M, Gispen F, et al: Oxytocin receptor DNA methylation in postpartum de-
pression. Psychoneuroendocrinology 69:150–160, 2016 27108164
Kimura T, Makino Y, Saji F, et al: Molecular characterization of a cloned human oxytocin recep-
tor. Eur J Endocrinol 131(4):385–390, 1994 7921228
Psychol Med 42(5):943–956, 2012 21995950
-
-
-
127 Psychoneuroendocrinology of Mood Disorders
https://t.me/med1917
King L, Robins S, Chen G, et al: Perinatal depression and DNA methylation of oxytocin-related
genes: a study of mothers and their children. Horm Behav 96:84–94, 2017 28918249
Kraszewska A, Ziemnicka K, Sowiński J, et al: No connection between long-term lithium treat-
ment and antithyroid antibodies. Pharmacopsychiatry 52(5):232–236, 2019 30731477
Krishna VN, Thunga R, Unnikrishnan B, et al: Association between bipolar affective disorder
and thyroid dysfunction. Asian J Psychiatr 6(1):42–45, 2013 23380316
Kroll-Desrosiers AR, Nephew BC, Babb JA, et al: Association of peripartum synthetic oxytocin
administration and depressive and anxiety disorders within the first postpartum year.
Depress Anxiety 34(2):137–146, 2017 28133901
Kupka RW, Nolen WA, Post RM, et al: High rate of autoimmune thyroiditis in bipolar disorder:
lack of association with lithium exposure. Biol Psychiatry 51(4):305–311, 2002 11958781
Lach G, Schellekens H, Dinan TG, Cryan JF: Anxiety, depression, and the microbiome: a role
for gut peptides. Neurotherapeutics 15(1):36–59, 2018 29134359
Lamers F, Vogelzangs N, Merikangas KR, et al: Evidence for a differential role of HPA axis func-
tion, inflammation and metabolic syndrome in melancholic versus atypical depression.
Mol Psychiatry 18(6):692–699, 2013 23089630
Landgraf R, Neumann I, Holsboer F, Pittman QJ: Interleukin-1beta stimulates both central and
peripheral release of vasopressin and oxytocin in the rat. Eur J Neurosci 7(4):592–598, 1995
7620610
Lanza di Scalea T, Pearlstein T: Premenstrual dysphoric disorder. Psychiatr Clin North Am
40(2):201–216, 2017 28477648
Lee MR, Sheskier MB, Farokhnia M, et al: Oxytocin receptor mRNA expression in dorsolateral
prefrontal cortex in major psychiatric disorders: a human post-mortem study. Psychoneu
roendocrinology 96:143–147, 2018 29940428
Li C, Lai J, Huang T, et al: Thyroid functions in patients with bipolar disorder and the impact
of quetiapine monotherapy: a retrospective, naturalistic study. Neuropsychiatr Dis Treat
15:2285–2290, 2019 31496710
Li Q, Zhang B, Cao H, et al: Oxytocin exerts antidepressant-like effect by potentiating dopami-
nergic synaptic transmission in the mPFC. Neuropharmacology 162:107836, 2020 31682854
Liamis G, Milionis H, Elisaf M: A review of drug-induced hyponatremia. Am J Kidney Dis
52(1):144–153, 2008 18468754
Lien YJ, Chang HH, Tsai HC, et al: Plasma oxytocin levels in major depressive and bipolar II
disorders. Psychiatry Res 258:402–406, 2017 28865715
Lombardo G, Enache D, Gianotti L, et al: Baseline cortisol and the efficacy of antiglucocorticoid
treatment in mood disorders: a meta-analysis. Psychoneuroendocrinology 110:104420,
2019 31499391
Long N, Nguyen L, Stevermer J: Priority Updates from the Research Literature (PURLs): it’s
time to reconsider early-morning testosterone tests. J Fam Pract 64(7):418–419, 2015
26324959
Ludwig B, Roy B, Dwivedi Y: Role of HPA and the HPG axis interaction in testosterone-medi-
ated learned helpless behavior. Mol Neurobiol 56(1):394–405, 2019 29704202
Mah BL: Oxytocin, postnatal depression, and parenting: a systematic review. Harv Rev Psychi-
atry 24(1):1–13, 2016 26735320
Manning M, Misicka A, Olma A, et al: Oxytocin and vasopressin agonists and antagonists as
research tools and potential therapeutics. J Neuroendocrinol 24(4):609–628, 2012 22375852
Maric NP, Adzic M: Pharmacological modulation of HPA axis in depression—new avenues for
potential therapeutic benefits. Psychiatr Danub 25(3):299–305, 2013 24048401
Masek K, Slánský J, Petrovický P, Hadden JW: Neuroendocrine immune interactions in health
and disease. Int Immunopharmacol 3(8):1235–1246, 2003 12860179
Matsubara T, Funato H, Kobayashi A, et al: Reduced glucocorticoid receptor alpha expression
in mood disorder patients and first-degree relatives. Biol Psychiatry 59(8):689–695, 2006
16458268
Matsuzaki M, Matsushita H, Tomizawa K, Matsui H: Oxytocin: a therapeutic target for mental
disorders. J Physiol Sci 62(6):441–444, 2012 23007624
-
128 The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
McEwen BS, Gray JD, Nasca C: 60 years of neuroendocrinology: redefining neuroendocrinol-
ogy: stress, sex and cognitive and emotional regulation. J Endocrinol 226(2):T67–T83, 2015
25934706
McHenry J, Carrier N, Hull E, Kabbaj M: Sex differences in anxiety and depression: role of tes-
tosterone. Front Neuroendocrinol 35(1):42–57, 2014 24076484
McLeod DS, Cooper DS: The incidence and prevalence of thyroid autoimmunity. Endocrine
42(2):252–265, 2012 22644837
McQuaid RJ, McInnis OA, Abizaid A, Anisman H: Making room for oxytocin in understanding
depression. Neurosci Biobehav Rev 45:305–322, 2014 25025656
Medici M, Direk N, Visser WE, et al: Thyroid function within the normal range and the risk of
depression: a population-based cohort study. J Clin Endocrinol Metab 99(4):1213–1219,
2014 24564323
Ménard C, Pfau ML, Hodes GE, Russo SJ: Immune and neuroendocrine mechanisms of stress
vulnerability and resilience. Neuropsychopharmacology 42(1):62–80, 2017 27291462
Menke A: Is the HPA axis as target for depression outdated, or is there a new hope? Front Psy-
chiatry 10:101, 2019 30890970
Meynen G, Unmehopa UA, van Heerikhuize JJ, et al: Increased arginine vasopressin mRNA
expression in the human hypothalamus in depression: a preliminary report. Biol Psychiatry 60(8):892–895, 2006 16499879
Miller KK, Perlis RH, Papakostas GI, et al: Low-dose transdermal testosterone augmentation
therapy improves depression severity in women. CNS Spectr 14(12):688–694, 2009
20394176
Min W, Liu C, Yang Y, et al: Alterations in hypothalamic-pituitary-adrenal/thyroid (HPA/
HPT) axes correlated with the clinical manifestations of depression. Prog Neuropsychopharmacol Biol Psychiatry 39(1):206–211, 2012 22750689
Mou Z, Huang Q, Chu SF, et al: Antidepressive effects of ginsenoside Rg1 via regulation of
HPA and HPG axis. Biomed Pharmacother 92:962–971, 2017 28618657
Nemeroff CB, Evans DL: Thyrotropin-releasing hormone (TRH), the thyroid axis, and affective
disorder. Ann NY Acad Sci 553:304–310, 1989 2497676
Neumann ID, Landgraf R: Balance of brain oxytocin and vasopressin: implications for anxiety,
depression, and social behaviors. Trends Neurosci 35(11):649–659, 2012 22974560
Neumann ID, Krömer SA, Toschi N, Ebner K: Brain oxytocin inhibits the (re)activity of the
hypothalamo-pituitary-adrenal axis in male rats: involvement of hypothalamic and limbic
brain regions. Regul Pept 96(1–2):31–38, 2000 11102649
Oakley RH, Cidlowski JA: The biology of the glucocorticoid receptor: new signaling mecha-
nisms in health and disease. J Allergy Clin Immunol 132(5):1033–1044, 2013 24084075
O’Donovan C, Kusumakar V, Graves GR, Bird DC: Menstrual abnormalities and polycystic
ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry
63(4):322–330, 2002 12000206
Osborne S, Biaggi A, Chua TE, et al: Antenatal depression programs cortisol stress reactivity in
offspring through increased maternal inflammation and cortisol in pregnancy: the Psychiatry Research and Motherhood—Depression (PRAM-D) Study. Psychoneuroendocrinology 98:211–221, 2018 30033161
Otmishi P, Gordon J, El-Oshar S, et al: Neuroimmune interaction in inflammatory diseases.
Clin Med Circ Respirat Pulm Med 2:35–44, 2008 21157520
Ozsoy S, Esel E, Kula M: Serum oxytocin levels in patients with depression and the effects of
gender and antidepressant treatment. Psychiatry Res 169(3):249–252, 2009 19732960
Ozsoy S, Mavili E, Aydin M, et al: Ultrasonically determined thyroid volume and thyroid func-
tions in lithium-naïve and lithium-treated patients with bipolar disorder: a cross-sectional
and longitudinal study. Hum Psychopharmacol 25(2):174–178, 2010 20196184
Palazidou E: The neurobiology of depression. Br Med Bull 101:127–145, 2012 22334281
Pariante CM: Glucocorticoid receptor function in vitro in patients with major depression. Stress
7(4):209–219, 2004 16019586
Pariante CM: Depression during pregnancy: molecular regulations of mothers’ and children’s
behaviour. Biochem Soc Trans 42(2):582–586, 2014 24646281
129 Psychoneuroendocrinology of Mood Disorders
https://t.me/med1917
Pariante CM: Why are depressed patients inflamed? A reflection on 20 years of research on
depression, glucocorticoid resistance and inflammation. Eur Neuropsychopharmacol
27(6):554–559, 2017 28479211
Pariante CM, Lightman SL: The HPA axis in major depression: classical theories and new de-
velopments. Trends Neurosci 31(9):464–468, 2008 18675469
Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to patho-
physiology and treatment. Biol Psychiatry 49(5):391–404, 2001 11274650
Pařízek A, Mikešová M, Jirák R, et al: Steroid hormones in the development of postpartum
depression. Physiol Res 63 (suppl 2):S277–S282, 2014 24908233
Parmentier T, Sienaert P: The use of triiodothyronine (T3) in the treatment of bipolar depres-
sion: a review of the literature. J Affect Disord 229:410–414, 2018 29331701
Parris MS, Grunebaum MF, Galfalvy HC, et al: Attempted suicide and oxytocin-related gene
polymorphisms. J Affect Disord 238:62–68, 2018 29860184
Pilhatsch M, Winter C, Nordström K, et al: Increased depressive behaviour in mice harboring
the mutant thyroid hormone receptor alpha 1. Behav Brain Res 214(2):187–192, 2010
20580649
Pope HG Jr, Cohane GH, Kanayama G, et al: Testosterone gel supplementation for men with
refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 160(1):105–
111, 2003 12505808
Pope HG Jr, Amiaz R, Brennan BP, et al: Parallel-group placebo-controlled trial of testosterone
gel in men with major depressive disorder displaying an incomplete response to standard
antidepressant treatment. J Clin Psychopharmacol 30(2):126–134, 2010 20520285
Rasgon NL, Altshuler LL, Gudeman D, et al: Medication status and polycystic ovary syndrome
in women with bipolar disorder: a preliminary report. J Clin Psychiatry 61(3):173–178,
2000 10817101
Rasgon NL, Altshuler LL, Fairbanks L, et al: Reproductive function and risk for PCOS in
women treated for bipolar disorder. Bipolar Disord 7(3):246–259, 2005 15898962
Rohr UD: The impact of testosterone imbalance on depression and women’s health. Maturitas
41 (suppl 1):S25–S46, 2002 11955793
Rutigliano G, Rocchetti M, Paloyelis Y, et al: Peripheral oxytocin and vasopressin: biomarkers
of psychiatric disorders? A comprehensive systematic review and preliminary metaanalysis. Psychiatry Res 241:207–220, 2016 27183106
Sachdeo RC, Wasserstein A, Mesenbrink PJ, D’Souza J: Effects of oxcarbazepine on sodium con-
centration and water handling. Ann Neurol 51(5):613–620, 2002 12112108
Salata RA, Jarrett DB, Verbalis JG, Robinson AG: Vasopressin stimulation of adrenocorticotro-
pin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF)
which provides evidence for CRF mediation of the diurnal rhythm of ACTH. J Clin Invest
81(3):766–774, 1988 2830315
Salk RH, Hyde JS, Abramson LY: Gender differences in depression in representative national
samples: meta-analyses of diagnoses and symptoms. Psychol Bull 143(8):783–822, 2017
28447828
Sanches M, Zunta-Soares GB, Hatch JP, et al: Gender differences in serum cortisol levels among
patients with major depressive disorder. Neuropsychiatria Neuropsychologia 8:89–93,
2013
Sawyer KM, Zunszain PA, Dazzan P, Pariante CM: Intergenerational transmission of depres-
sion: clinical observations and molecular mechanisms. Mol Psychiatry 24(8):1157–1177,
2019 30283036
Schiller CE, Johnson SL, Abate AC, et al: Reproductive steroid regulation of mood and behav-
ior. Compr Physiol 6(3):1135–1160, 2016 27347888
Schmider J, Lammers CH, Gotthardt U, et al: Combined dexamethasone/corticotropin-releas-
ing hormone test in acute and remitted manic patients, in acute depression, and in normal
controls: I. Biol Psychiatry 38(12):797–802, 1995 8750037
Schmidt PJ, Rubinow DR: Sex hormones and mood in the perimenopause. Ann NY Acad Sci
1179:70–85, 2009 19906233
130 The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
Schmidt PJ, Ben Dor R, Martinez PE, et al: Effects of estradiol withdrawal on mood in women
with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry
72(7):714–726, 2015 26018333
Sforzini L, Nettis MA, Mondelli V, Pariante CM: Inflammation in cancer and depression: a star-
ring role for the kynurenine pathway. Psychopharmacology (Berl) 236(10):2997–3011, 2019
30806743
Shen Y, Wu F, Zhou Y, et al: Association of thyroid dysfunction with suicide attempts in first-
episode and drug naïve patients with major depressive disorder. J Affect Disord 259:180–
185, 2019 31446378
Sher L, Grunebaum MF, Sullivan GM, et al: Testosterone levels in suicide attempters with bi-
polar disorder. J Psychiatr Res 46(10):1267–1271, 2012 22858352
Sher L, Grunebaum MF, Sullivan GM, et al: Association of testosterone levels and future sui-
cide attempts in females with bipolar disorder. J Affect Disord 166:98–102, 2014 25012416
Smart C, Strathdee G, Watson S, et al: Early life trauma, depression and the glucocorticoid re-
ceptor gene—an epigenetic perspective. Psychol Med 45(16):3393–3410, 2015 26387521
Spasovski G, Vanholder R, Allolio B, et al; Hyponatraemia Guideline Development Group:
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol
170(3):G1–G47, 2014 24569125
Stetler C, Miller GE: Depression and hypothalamic-pituitary-adrenal activation: a quantitative
summary of four decades of research. Psychosom Med 73(2):114–126, 2011 21257974
Subramaniam A, LoPilato A, Walker EF: Psychotropic medication effects on cortisol: implica-
tions for research and mechanisms of drug action. Schizophr Res 213:6–14, 2019 31307858
Sudo N: Microbiome, HPA axis and production of endocrine hormones in the gut. Adv Exp
Med Biol 817:177–194, 2014 24997034
Surget A, Belzung C: Involvement of vasopressin in affective disorders. Eur J Pharmacol 583(2–
3):340–349, 2008 18255056
Swaab DF, Bao AM, Lucassen PJ: The stress system in the human brain in depression and neu-
rodegeneration. Ageing Res Rev 4(2):141–194, 2005 15996533
Ta ká cs L, Seidlerová JM, Štěrbová Z, et al: The effects of intrapartum synthetic oxytocin on ma-
ternal postpartum mood: findings from a prospective observational study. Arch Women
Ment Health 22(4):485–491, 2019 30306269
Taub DD: Neuroendocrine interactions in the immune system. Cell Immunol 252(1–2):1–6, 2008
18619587
Toni R: The neuroendocrine system: organization and homeostatic role. J Endocrinol Invest
27(6 suppl):35–47, 2004 15481802
Toufexis D, Rivarola MA, Lara H, Viau V: Stress and the reproductive axis. J Neuroendocrinol
26(9):573–586, 2014 25040027
Tsuru J, Ishitobi Y, Ninomiya T, et al: The thyrotropin-releasing hormone test may predict re-
currence of clinical depression within ten years after discharge. Neuroendocrinol Lett
34(5):409–417, 2013 23922049
Turan T, Uysal C, Asdemir A, Kılıç E: May oxytocin be a trait marker for bipolar disorder? Psy-
choneuroendocrinology 38(12):2890–2896, 2013 24080188
Ulrich-Lai YM, Herman JP: Neural regulation of endocrine and autonomic stress responses.
Nat Rev Neurosci 10(6):397–409, 2009 19469025
van Bodegom M, Homberg JR, Henckens MJAG: Modulation of the hypothalamic-pituitary-
adrenal axis by early life stress exposure. Front Cell Neurosci 11:87, 2017 28469557
van Londen L, Kerkhof GA, van den Berg F, et al: Plasma arginine vasopressin and motor ac-
tivity in major depression. Biol Psychiatry 43(3):196–204, 1998 9494701
van West D, Del-Favero J, Aulchenko Y, et al: A major SNP haplotype of the arginine vasopres-
sin 1B receptor protects against recurrent major depression. Mol Psychiatry 9(3):287–292,
2004 15094789
Verbalis JG: Disorders of water metabolism: diabetes insipidus and the syndrome of inappro-
priate antidiuretic hormone secretion. Handb Clin Neurol 124:37–52, 2014 25248578
131 Psychoneuroendocrinology of Mood Disorders
https://t.me/med1917
Verburg-van Kemenade BML, Cohen N, Chadzinska M: Neuroendocrine-immune interaction:
evolutionarily conserved mechanisms that maintain allostasis in an ever-changing envi
ronment. Dev Comp Immunol 66:2–23, 2017 27296493
Vlainić JV, Šuran J, Vlainić T, Vu ko re p AL: Probiotics as an adjuvant therapy in major depres-
sive disorder. Curr Neuropharmacol 14(8):952–958, 2016 27226112
Vonk R, van der Schot AC, Kahn RS, et al: Is autoimmune thyroiditis part of the genetic vulner-
ability (or an endophenotype) for bipolar disorder? Biol Psychiatry 62(2):135–140, 2007
17141745
Walshaw PD, Gyulai L, Bauer M, et al: Adjunctive thyroid hormone treatment in rapid cycling
bipolar disorder: a double-blind placebo-controlled trial of levothyroxine (L-T4) and
triiodothyronine (T3). Bipolar Disord 20(7):594–603, 2018 29869405
Walther A, Breidenstein J, Miller R: Association of testosterone treatment with alleviation of de-
pressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry
76(1):31–40, 2019 30427999
Watanuki T, Funato H, Uchida S, et al: Increased expression of splicing factor SRp20 mRNA in
bipolar disorder patients. J Affect Disord 110(1–2):62–69, 2008 18281098
Watson S, Gallagher P, Ritchie JC, et al: Hypothalamic-pituitary-adrenal axis function in pa-
tients with bipolar disorder. Br J Psychiatry 184:496–502, 2004 15172943
Wesseloo R, Kamperman AM, Bergink V, Pop VJM: Thyroid peroxidase antibodies during
early gestation and the subsequent risk of first-onset postpartum depression: a prospective
cohort study. J Affect Disord 225:399–403, 2018 28850854
Wooderson SC, Gallagher P, Watson S, Young AH: An exploration of testosterone levels in pa-
tients with bipolar disorder. BJPsych Open 1(2):136–138, 2015 27703738
Wysokiński A, Kłoszewska I: Level of thyroid-stimulating hormone (TSH) in patients with
acute schizophrenia, unipolar depression or bipolar disorder. Neurochem Res 39(7):1245–
1253, 2014 24723220
Yatham LN: Prolactin and cortisol responses to fenfluramine challenge in mania. Biol Psychia-
try 39(4):285–288, 1996 8645775
Yonkers KA, Simoni MK: Premenstrual disorders. Am J Obstet Gynecol 218(1):68–74, 2018
28571724
Young AH, Gallagher P, Watson S, et al: Improvements in neurocognitive function and mood
following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsy
chopharmacology 29(8):1538–1545, 2004 15127079
Zada G, Carmichael JD, Selman WR: Introduction: Cushing’s disease: a century of evolving
diagnostics and therapeutics for an often elusive entity. Neurosurg Focus 38(2):E1, 2015
25639311
Zhao T, Chen BM, Zhao XM, Shan ZY: Subclinical hypothyroidism and depression: a meta-
analysis. Transl Psychiatry 8(1):239, 2018 30375372
Zik JB, Roberts DL: The many faces of oxytocin: implications for psychiatry. Psychiatry Res
226(1):31–37, 2015 25619431
Zunszain PA, Hepgul N, Pariante CM: Inflammation and depression. Curr Top Behav Neurosci
14:135–151, 2013 22553073
-
-
Соседние файлы в папке Библиотека им академика М.И. Перельмана